Neuroprotective Properties Under Investigation The Zagreb groups 2016 review in Current Neuropharmacology described peripheral BPC-157 administration altering serotonin synthesis rates in specific brain regions, particularly nigrostriatal and other dopaminergic pathways (Tohyama, Sikiric, Diksic, 2004, Life Sciences )
There are two levels available: a 250 mcg level, ideal for people needing maintenance
In sheer numbers, that means that while 8,722 Americans in this age group took a GLP-1 in 2020, 60,567 were doing so by the end of 2023
Retrieved 21 April 2025
When prescribed appropriately, monitored by a qualified clinician, and manufactured under strict FDA standards, these drugs can be safe and effective tools for people working to improve their health